A novel organoselenium compound induces cell cycle arrest and apoptosis in prostate cancer cell lines

Biochemical and Biophysical Research Communications

Volumn 309, Issue 3, 2003, Pages 578-583

  Shi, Changjin ^a   Yu, Lizhang ^a   Yang, Fengguang ^a   Yan, Jun ^b   Zeng, Huihui ^b  

^a PEKING UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Anticancer agent; Apoptosis; Cdks; Cell block; Cell cycle; Cyclins; Organoselenium compound; Prostate cancer

Indexed keywords

1,2 BIS(1,2 BENZISOSELENAZOLONE 3(2H) KETONE)ETHANE; ANTINEOPLASTIC AGENT; CYCLIN A; CYCLIN B1; CYCLIN D1; CYCLIN E; ENZYME INHIBITOR; ORGANOSELENIUM DERIVATIVE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; THIOREDOXIN REDUCTASE; THIOREDOXIN REDUCTASE INHIBITOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE S PHASE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG SCREENING; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN ANALYSIS;

CYCLINA;

EID: 0041829414     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2003.08.032     Document Type: Article

References (26)

1. Holmgren A. Thioredoxin. Annu. Rev. Biochem. 54:1985;237-271.
2. Laurent T.C., Moore E.C., Reichard P. Enzymatic synthesis of deoxyribonucleotides. Isolation and characterization of thioredoxin, the hydrogen donor from Escherichia coli. J. Biol. Chem. 239:1964;3436-3444.
3. Matthews J.R., Wakasugi N., Virelizier J.L., Yodoi J., Hay R.T. Thioredoxin regulates the DNA binding activity of NF-κB by reduction of a disulfide bond involving cysteine 62. Nucleic Acids Res. 20:1992;3821-3830.
4. Galter D., Mihm S., Dro ge W. Distinct effects of glutathione disulphide on the nuclear transcription factors κB and the activator protein-1. Eur. J. Biochem. 221:1994;639-648.
5. Berggren M., Gallegos A., Gasdaska J.R., Gasdaska P.Y., Warneke J., Powis G. Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer Res. 16:1996;3459-3466.
6. Gasdaska P.Y., Oblong J.E., Cotgreave I.A., Powis G. The predicted amino acid sequence of human thioredoxin is identical to that of the autocrine growth factor human adult T-cell derived factor (ADF): thioredoxin mRNA is elevated in some human tumors. Biochim. Biophys. Acta. 1218:1994;292-296.
7. Nakamura H., Masutani H., Tagaya Y., Yamauchi A., Inamoto T., Nanbu Y., Fujii S., Ozawa K., Yodoi J. Expression and growth-promoting effect of adult T-cell leukemia-derived factor. A human thioredoxin homologue in hepatocellular carcinoma. Cancer. 69:1992;2091-2097.
8. Gasdaska J.R., Berggren M., Powis G. Cell growth stimulation by the redox protein thioredoxin occurs by a novel helper mechanism. Cell Growth Differ. 6:1995;1642-1650.
9. Powis G., Kirkpatrick D.L., Angulo M., Gasdaska J.R., Broome Powell M., Salmon S.E., Montfort W.R. Thioredoxin redox signaling: a novel target for anti-cancer drug development. Anticancer Drugs. 7(Suppl 3):1996;121-126.
10. Deng S.J., Kuang B., Zhou X., Yan J., Zhao F., Jia X.Y., Zeng H.H. BBSKE, 1,2-[bis(1,2-benzisoselenazolone-3(2H)-ketone)] ethane, induced cell death in tumor cells. J. Peking Univ. (Health Sciences). 35:2003;108-109.
11. Hill K.E., McCollum G.W., Boeglin M.E., Burk R.F. TrxR activity is decreased by selenium deficiency. Biochem. Biophys. Res. Commun. 234:1997;293-295.
12. Greenlee R.T., Hill-Harmon M.B., Murray T., Thun M. Cancer statistics. CA. Cancer J. Clin. 51:2001;15-36.
13. Rini B.I., Small E.J. Prostate cancer update. Curr. Opin. Oncol. 14:2002;286-291.
14. Mohler J.L., Morris T.L., Ford O.H., Alvey R.F., Sakamoto C., Gregory C.W. Identification of differentially expressed genes associated with androgen-independent growth of prostate cancer. Prostate. 51:2002;247-255.
15. Yokomizo A., Ono M., Nanri H., Makino Y., Ohga T., Wada M., Okamoto T., Yodoi J., Kuwano M., Kohno K. Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. Caner Res. 55:1995;293-296.
16. Sherr C.J. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res. 60:2000;3689-3695.
17. Xiong Y., Hannon G.J., Zang H., Casso D., Kobayashi R., Beach D. p21 is a universal inhibitor of cyclin kinase. Nature. 366:1993;701-704.
18. Harper J.W., Adami G.R., Wei N., Keyomarsi K., Elledge S.J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin idependent kinases. Cell. 75:1993;805-816.
19. El-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., Vogelstein B. WAF-1, a potential mediator of p53 tumour suppression. Cell. 75:1993;817-825.
20. Dulic V., Lees E., Reed S.I. Association of human cyclin E with a periodic G1-S phase protein kinase. Science. 257:1992;1958-1961.
21. Ahmad N., Cheng P., Mukhtar H. Cell cycle dysregulation by green tea polyphenol epigallocatechin-3-gallate. Biochem. Biophys. Res. Commun. 275:2000;328-334.
22. Sherr C.J. Mammalian G1 cyclins. Cell. 73:1993;1059-1065.
23. Sherr C.J. Cancer cell cycles. Science. 274:1996;1672-1677.
24. Huang P., Ballal K., Plunkett W. Biochemical characterization of the protein activity responsible for high molecular weight DNA fragmentation during drug-induced apoptosis. Cancer Res. 57:1997;3407-3414.
25. Salomons G.S., Brady H.J., Verwijs-Janssen M., Van Den Berg J.D., Hart A.A., Van Den Berg H., Behrendt H., Hahlen K., Smets L.A. The Bax alpha:Bcl-2 ratio modulates the response to dexamethasone in leukaemic cells and is highly variable in childhood acute leukaemia. Int. J. Cancer. 71:1997;959-965.
26. Sedlak T.W., Oltvai Z.N., Yang E., Wang K., Boise L.H., Thompson C.B., Korsmeyer S.J. Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proc. Natl. Acad. Sci. USA. 92:1995;7834-7838.